ArticleMedicine and pharmacy reports2026
Renal calcifications and primary hyperpara-thyroidism in a tertiary care hospital center of North Africa: a single-center experience.
Article in Medicine and pharmacy reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Primary hyperparathyroidism (PHPT) is a common endocrine disorder; one of its common complications is renal calcifications. Our study aimed to determine the prevalence of renal calcifications (nephrolithiasis and nephrocalcinosis) in patients with primary hyperparathyroidism, to elucidate potential demographic, biochemical, radiological, and histological differences between patients with and without renal calcifications, and to assess potential risk factors associated with its occurrence. Methods: This was a retrospective, single-center, descriptive, and analytical study involving 62 patients with primary hyperparathyroidism (PHPT). Participants were assessed through serum and urinary parameters, kidney-urinary tract ultrasonography, and abdominal computed tomography (CT) scans to evaluate the presence or absence of renal calcifications. Results: We found 30 patients (48.4%) with renal calcifications, all of them nephrolithiasis, and only 2 cases (6.7%) had nephrocalcinosis associated with nephrolithiasis; and they were all detected by abdominal CT scan. Compared to patients without renal calcifications, those who had renal calcifications had a significantly higher prevalence of diabetes, BMI, waist circumference, PTH 1-84, alkaline phosphatase, and lower 25-hydroxy vitamin D (25-(OH)-D). No significant difference was found between the two groups in other studied parameters. Higher BMI and lower 25-(OH)-D were potential risk factors for renal calcifications in multivariate regression analysis. Conclusion: The combination of PHPT and renal calcifications is still common and often asymptomatic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.